scholarly journals Unexpected Change in Thyroglobulin Concentration

2017 ◽  
Vol 63 (11) ◽  
pp. 1775-1775
Author(s):  
Amanda M Hopp ◽  
Pratistha Ranjitkar ◽  
Jessica M Colon-Franco
2014 ◽  
Vol 16 (3) ◽  
pp. 164-167 ◽  
Author(s):  
Akira Hayakawa ◽  
Kotaro Matoba ◽  
Kie Horioka ◽  
Manabu Murakami ◽  
Koichi Terazawa

1984 ◽  
Vol 30 (1) ◽  
pp. 81-86 ◽  
Author(s):  
M F Bayer ◽  
I R McDougall

Abstract We compared two commercial assays for measurement of serum thyroglobulin [Nuclear Medical Systems (NMS) and "CIS" (Damon Diagnostics)] with each other and with one developed at Stanford (J Clin Endocrinol Metab 49:557-564, 1979). The NMS assay is a competitive-binding RIA, the CIS and Stanford assays are two-site immunoradiometric assays. The kit standards varied in thyroglobulin concentration. The NMS standards differed in immunoreactivity from thyroglobulin in clinical specimens and from the other standards. Also, nonparallelism between standards and patients' sera in the NMS assay suggested a less-specific antiserum. Results by the CIS and Stanford assays correlated well (n = 120, r = 0.964), those by the NMS assay less strongly (n = 101, r = 0.855 vs CIS, r = 0.888 vs Stanford). Clinical evaluation in 50 patients treated for differentiated thyroid carcinoma (10 with metastases and 40 currently disease-free) indicated good agreement for positive results by the three assays. The CIS and the Stanford assay both gave high results (greater than or equal to 25 micrograms/L) in all 10 cases with metastases; the NMS RIA identified eight of these patients (thyroglobulin greater than or equal to 30 micrograms/L), but excluded two with anti-thyroglobulin autoantibodies. In subjects without disease, however, the percentage of undetectable thyroglobulin (negative result), as opposed to low measurable thyroglobulin (inconclusive result) varied considerably: 85% by CIS, 30% by NMS, and 75% by the Stanford assay.


1992 ◽  
Vol 126 (3) ◽  
pp. 233-237 ◽  
Author(s):  
Boonsong Ongphiphadhanakul ◽  
Rajata Rajatanavin ◽  
Surtrong Chiemchanya ◽  
La-or Chailurkit ◽  
Atana Kongsuksai ◽  
...  

In this study, we identified clinical and laboratory markers of malignant thyroid nodules and determined whether systematic inclusion of these data could improve diagnostic accuracy of fine-needle aspiration biopsy in solitary thyroid nodules. The patients were 24 men and 105 women who underwent surgical removal of solitary thyroid nodules and had adequate fine-needle aspiration biopsy performed prior to surgery. Including fine-needle aspiration biopsy's diagnosis of suspected of malignancy in the same category as malignancy, the sensitivity and specificity of fine-needle aspiration biopsy were 71.4% and 85.1%, respectively, with an accuracy of 82.2%. Using stepwise linear regression analysis, clinical data, i.e. increasing age, irregular nodule surface, hard consistency of nodule, and high serum thyroglobulin concentration, were associated with an increased risk of malignancy when the cytological result was excluded. When cytology was also considered, male sex, irregular nodule surface and high serum thyroglobulin concentration were found to be associated with an increased risk of malignancy. The diagnostic value of clinical data alone, even in combination with cytology or laboratory data, was inferior to that of fine-needle aspiration biopsy alone. The specificity and accuracy of fine-needle aspiration biopsy could be increased to 98.0% and 90.7%, respectively, whereas its sensitivity was decreased to 64.3% when these variables were considered in combination. Therefore, of fine-needle aspiration biopsy, clinical and laboratory data, fine-needle aspiration biopsy alone has the highest diagnostic value, which can be increased only when both clinical characteristics and serum thyroglobulin concentration are systematically included.


2000 ◽  
Vol 298 (1-2) ◽  
pp. 69-84 ◽  
Author(s):  
Ryoji Kato ◽  
Masayuki Maruyama ◽  
Tetsuo Sekino ◽  
Yoshio Kasuga

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Sheila A Skeaff ◽  
Christine D Thomson ◽  
Winsome R Parnell

2004 ◽  
Vol 43 (04) ◽  
pp. 115-120 ◽  
Author(s):  
J. Dressler ◽  
J. Farahati ◽  
F. Grünwald ◽  
B. Leisner ◽  
E. Moser ◽  
...  

SummaryThe procedure guidelines for radioiodine therapy (RIT) of differentiated thyroid cancer (version 2) are the counterpart to the procedure guidelines for 131I whole-body scintigraphy (version 2) and specify the interdisciplinary guidelines for thyroid cancer of the Deutsche Krebs-gesellschaft and the Deutsche Gesellschaft für Chirurgie concerning the nuclear medicine part. Compared with version 1 facultative options for RIT can be chosen in special cases: ablative RIT for papillary microcarcinoma ≤1 cm, ablative RIT for mixed forms of anaplastic and differentiated thyroid cancer, and RIT in patients with a measurable or increasing thyroglobulin concentration but without detectable metastases by imaging. The description of the pretherapeutic dosimetry now includes the isotopes 123I and 124I as well as a broader range of the activity of 131I. Activities of 2-5 GBq 131I are recommended for the first ablative RIT. If high accumulative activities of 131I are expected, men who have not yet finished their family planning should be advised to the option of sperm cryoconservation. An interdisciplinary consensus is necessary whether the new TNM-classification (UICC, 6th edition, 2002) will lead to modified recommendations for surgical or nuclear medicine therapy, especially for the surgical completeness and for the ablative RIT of pT1 papillary cancer.


1983 ◽  
Vol 29 (1) ◽  
pp. 56-59 ◽  
Author(s):  
T J Wilke

Abstract I compared values for the free thyroxin index derived from data obtained by four triiodothyronine-uptake kits for 93 euthyroid subjects with normal or altered thyroxin-binding globulin binding capacity. In addition, I devised a mathematical model of an "ideal" free thyroxin index. Only one uptake kit satisfactorily normalized values for the free thyroxin index in the increased thyroglobulin groups, as compared with the control. The other three demonstrated contrasting patterns of free thyroxin index variation as compared with normal, when thyroglobulin concentrations were increased. By all four uptake tests, values for the free thyroxin index in thyroglobulin-deficient patients were significantly lower than normal. Values derived from one uptake kit behaved similarly to those of the "ideal" model. The failure of the free thyroxin index to compensate for increases in thyroglobulin concentration is therefore a function of specific uptake methods rather than a characteristic of free thyroxin index per se. However, the free thyroxin index is not a true reflection of thyroid status in patients with thyroglobulin deficiency. The model suggests that a curvilinear relationship between triiodothyronine uptake and the concentration of thyroxin-binding globulin can result in a free thyroxin index that corrects for increases in thyroglobulin binding capacity.


2016 ◽  
Vol 5 (2) ◽  
pp. 120-124 ◽  
Author(s):  
Eftychia Koukkou ◽  
Ioannis Ilias ◽  
Irene Mamalis ◽  
Georgios G. Adonakis ◽  
Kostas B. Markou

Thyroid ◽  
2005 ◽  
Vol 15 (12) ◽  
pp. 1355-1361 ◽  
Author(s):  
Rossella Elisei ◽  
Cristina Romei ◽  
Maria Grazia Castagna ◽  
Simonetta Lisi ◽  
Agnese Vivaldi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document